smallcap sleuth

smallcap sleuth
Send Message
View as an RSS Feed
  • Biotech Is The Bet In 2016  [View instapost]
    Hi Bret, thanks for the thoughts. I'd like to make you aware of 2 companies I think you will like and possibly do a little research into. A rapidly or very soon to be VERY RAPIDLY growing mini pharma, generic, TLGT. And AXDX a revolution about to happen in hospital treatment of infection. Both have a lot of runway directly in front of them.

    AXDX management is not only proven but has put its money in direct and overwhelming size along side outside stockholders. No one yet follows either of these gems.
    Dec 20, 2015. 11:51 AM | Likes Like |Link to Comment
  • Reeds: Slow Quarter Reveals Premium Valuation  [View article]
    Gee wHat happened to all those comments years ago , wait Coke is a buyer. Finally the dickshun gave up on that line of hope. Anybody listening to the buy and wait guys should BEWARE this is a loser company and its destined to be an orphan stand alone lister with no future except unique excuses quarter after quarter. And it's illiquid once you are in you are trapped, scarce buyers and they gave to be really naive. Nice product invest your money in an overpriced 4 pack.
    Nov 15, 2015. 10:28 AM | 1 Like Like |Link to Comment
  • IGI Laboratories : Nothing If Not Volatile  [View article]
    It's months later in mid Nov. now but the company did some great things recently. Another product already marketable and the purchase of a profitable Canadian platform doing $3 million that will be fairly easy to provide additional product to both organic and from their contract manufacturers in Europa! They have said they expect to exit '16 with a run rate of $130 million almost 2times it's current revenues and I think that is really likely to be closer to $150-160 with '17 at least 50% above that. It they can net 15% on their 50 million common out the stock should do much bigger numbers. The risk is minimal as these are generics no phase 3 surprise failures. Excellent smart careful management with growth in the front lobes of their hard working brains. I see $20 mid 16. Biggest risk is delay of approvals of the company's GDUFA 3&4 year filings which should manifest by latest Qi 16. Many additions to the pipeline due in Dec as short term catalyst.
    Nov 13, 2015. 08:22 AM | Likes Like |Link to Comment
  • IGI Laboratories : Nothing If Not Volatile  [View article]
    Unfortunately NOT, I tried
    Nov 13, 2015. 08:09 AM | Likes Like |Link to Comment
  • Reeds: Slow Quarter Reveals Premium Valuation  [View article]
    Lol somehow Reeds has a loyal following of idiot shareholders it's always wait the management by hippie Chris must all be smoking dope in Colorado or on medical in Cali. Gee do I hear Come is a buyer? That must be .00000001% even if they grew it 100 times. Nice small private company to give to your Eco kid, he'd do better than this guy. You guys are so committed and blind. I'm back after 2 years and it's still the same company story and commentary. They can't even hit their foot with a shotgun! Lol so glad I sold years ago at 6 when they couldn't deliver, still can't.
    Nov 13, 2015. 08:06 AM | 1 Like Like |Link to Comment
  • Reeds: Slow Quarter Reveals Premium Valuation  [View article]
    You have been saying that forYEARS they are losers and so are you
    Nov 13, 2015. 08:00 AM | Likes Like |Link to Comment
  • IG Labs down big premarket after Q1 miss  [View news story]
    Apr 29, 2015. 11:15 AM | Likes Like |Link to Comment
  • MiMedx Group beats by $0.01, misses on revenue  [View news story]
    Like a runaway freight train, just keeps getting better and better. For the cynics yeah it can't keep growing at the rate as per the law of large numbers but bottom line WOW
    Apr 28, 2015. 04:27 AM | 1 Like Like |Link to Comment
  • Accelerate Diagnostics: Mistakenly Rewarded And Destined To Crash?  [View article]
    Company is about to enter a new zone- that of a CE and submission to the FDA should be I believe any day. Sooner thE better if f you are a share holder, unless some of us holders are looking for a pop to exit. I've learned " you never can be certain sin about almost anything in the market" !
    I liked the " at the market buy" by Director Schuler, his grand kids have quite an appetite! Lucky inheritors, hope the fortune doesn't ruin them! This stock is getting thinner and thinner, I don't think any funds or institutions are going to leave before the product hits the market and we see the rate of uptake by the hospital community. If it's aggressive one should wait until the company by passes the blood culturing requirement then it's super boom time. At that point they will own the future and the multiple will expand like crazy.
    The ISO opens the company for the CE I can hardly wait. I think some hard news will have a large immediate effect.
    Apr 27, 2015. 09:24 AM | Likes Like |Link to Comment
  • Accelerate Diagnostics: Mistakenly Rewarded And Destined To Crash?  [View article]
    Apr 27, 2015. 09:12 AM | 1 Like Like |Link to Comment
  • IGI Labs eases after announcement of debt offering  [View news story]
    Crazy! Total bull transaction. Company does $20 million in first 3/4 of this year with essential break even profit/loss. Supposed to earn $2-3 million in 4th Q. Is able to borrow $125 million at 3.75 % with convert strike at $11.29 where buyers can't convert until 9/19. Very very cheap money because they have a huge pipeline already filed with the FDA for topicals and newly purchased injectibiles from Astra Z ( 17 ) and 3-4 from Valeant. Will no doubt use the funds to acquire a company or facility enabling IG. To manufacture injectibiles. Biggest problem is the unacceptable time the FDA is taking to move the ANDAs through the process. Beginning of Super growth of earnings will likely be late '15 or early '16 unless a legacy of 2010 and 2011 ANDAs get the go ahead but that is in the hands of the FDA. If you can wait this is going to triple from here by late '17. Guarantee, but don't look for a money back guarantee !
    Dec 12, 2014. 12:35 PM | 1 Like Like |Link to Comment
  • Zacks' Bull Of The Day: MiMedx  [View article]
    This looks like an extra group of patent protected products with very effective outcomes on patients. Seems early in its market penetration. Management seems stock holder friendly with the comment last quarter that they are making free cash and don't need to invest in an acquisition so could start buying back stock. Weakness could be an opportunity for them to shrink the shares outstanding. High quality management gives it to you straight.
    Dec 12, 2014. 12:10 PM | 1 Like Like |Link to Comment
  • Accelerate Diagnostics: Mistakenly Rewarded And Destined To Crash?  [View article]
    Disagree with your contention completly. Your info is incorrect the dropping caused an immediate multimillion share sell off, or did multimillion shares all of a sudden decide to hit the market on just those 2 days. Company WILL ACHIEVE its goals of revolutionizing the methodology of short term diagnostic on bacteria. Most important advance in a hundred plus years! Welcome to the twenty first century. Can hardly wait until it's filed and in the marketplace. Sort of reminds me of the way Syntex went ballistic in 1964, they had a monopoly on the birth control pill. This will have a monopoly on a vast life saving invention. When this gets going ( stock wise ) it will be beautiful to watch and joyful to own a large chunk!
    Oct 25, 2014. 11:43 AM | Likes Like |Link to Comment
  • IGI Laboratories: Management Has Delivered And The Pipeline Is Building  [View article]
    Will did you attend the quarterly? One heck of a story and performance. Check it out. Revs and profits in 2nd half '15, yes 15 and major build in pipeline in 15 due to mature early thru FDA. This co has its sht together and has plans and brains and determination to make it all happen. Hope you bot on the mini pull back, stock might be very reasonably priced as they project earnings of $2-3 M this year. Due to price rises and early seeming acceptance - multiply that by 4 but subtract significant R N D spend in 15, 1 new ANDA per month (3-4 in pipeline) current plus , '15 add 12. Yes they thought due to 9 of 18 bot from AZ are on FDA shortage list possible, hopeful quicker approval of new supplier which they thought could be ready for market second half of '15.

    Terrificic presentation. No commitment to earnings in 15 but should be profitable, no estimate. Maybe likely in 4th Q conf call after they absorb market reaction to new higher prices!
    They thought
    Oct 24, 2014. 05:41 PM | Likes Like |Link to Comment
  • IGI Laboratories: Management Has Delivered And The Pipeline Is Building  [View article]
    Will I think you missed that AZ. Is going to produce the drugs for IG that should mean sakes and possible profits in '16. I think during that period IG A will buy or merge with the sought after capability.
    Oct 23, 2014. 02:52 PM | Likes Like |Link to Comment